About Lumos Diagnostics
Lumos Diagnostics is a company based in Carlsbad (United States) founded in 2017. Lumos Diagnostics has raised $40 million across 3 funding rounds from investors including Planet Innovation, Perennial Partners and Ellerston Capital. Lumos Diagnostics operates in a competitive market with competitors including Access Bio, SD Biosensor, Fluxergy, Module Innovations and DxGen, among others.
- Headquarter Carlsbad, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website lumosdiagnostics.com
- Social LinkedIn X YouTube
- Legal Name Lumos Diagnostics Holdings Limited
- Annual Revenue$13.41 M (USD)1.68as on Jun 30, 2026
- Net Profit-$5.03 M (USD)34.11as on Jun 30, 2026
- EBITDA-$11.78 M (USD)-99.81as on Jun 30, 2026
- Total Equity Funding$40M (USD)
in 3 rounds
- Latest Funding Round$20M (USD), Post-IPO
Mar 2026
- InvestorsPlanet Innovation
& 2 more
Apps and channels of Lumos Diagnostics
its YouTube channel Lumos Diagnostics has 50 subscribers and 14 videos.
Videos from Lumos Diagnostics
The most watched videos on Lumos Diagnostics's YouTube channel, Lumos Diagnostics (50 subscribers). Click a video to play it here.
More on Lumos Diagnostics.
Funding Insights of Lumos Diagnostics
Lumos Diagnostics has successfully raised a total of $40M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 3
- Last Round Post-IPO — $20M
- First Round $15M
(Feb 2020)
- Investors Count 3
All 3 funding rounds of Lumos Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $20M | Post-IPO | – | – | – |
| Oct 2020 | $25M | Series B | – | Ellerston Capital, Perennial | – |
| Feb 2020 | $15M | Series A | – | Planet Innovation | – |
3 investors in total: 3 institutional.
Investors in Lumos Diagnostics
Lumos Diagnostics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Planet Innovation, Perennial Partners and Ellerston Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management services are provided by Ellerston Capital. | 2002 | ellerstoncapital.com | Sydney, Australia | |
Diversified asset management services are provided in Australia. | 2000 | perennial.net.au | Sydney, Australia | |
End-to-end healthtech product development and manufacturing services are offered. | 2009 | planetinnovation.com | Box Hill, Australia |
Investor details for Lumos Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lumos Diagnostics
30 people are tracked at Lumos Diagnostics (12 in leadership, 4 in board & advisors, 14 in team).
| Name | Role | Group |
|---|---|---|
Sacha Dopheide | CEO | Leadership |
Roderick Chanchico | Director Of Manufacturing | Leadership |
Sue Hibbeln | VP, Quality & Regulatory Affairs | Leadership |
Barrie Lambert | Chief Financial Officer | Leadership |
Sarah Glubka | Vice President Human Resources | Leadership |
Doug Ward | CEO | Leadership |
Annie Bell | Vice President Medical Affairs | Leadership |
Jon Gary | Vice President Of Research & Development | Leadership |
Sandra Nelson | Sr. Director FP&A | Leadership |
Susan Hibbeln, MS, RAC | Vice President, Quality And Regulatory Affairs | Leadership |
Tommy Hall | Director US Sales | Leadership |
Anthony Favaloro | Vice President Operations | Leadership |
Bronwyn Le Grice | Director | Board & advisors |
Catherine Robson | Director | Board & advisors |
Lawrence Mehren | Director | Board & advisors |
Sam Lanyon | Executive Chair | Board & advisors |
Rency M. | Research Associate II | Team |
Paul Kase | SVP, Commercial Operations | Team |
Aswathi Cheeniyil | Scientist, Process Transfer/operations | Team |
Alexandra Leyte-Vidal | Scientist I | Team |
10 more people are available in the full profile.
Complete people profiles for Lumos Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lumos Diagnostics
Lumos Diagnostics is a publicly listed company on the ASX with ticker symbol LDX in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Jul 2021
- Listed onASX: LDX
- Listed entityLUMOS DIAGNOSTICS HOLDINGS LIMITED
- Exchange sectorHealth technology
- ISINAU0000157091
- Share price0.10 AUD (-4.76% on the day) · 2026-10-09
- Market capitalisation102,024,954.00 AUD
- EPS (diluted, trailing year)-0.01 AUD
- Volume (last session)770,002
Financials of Lumos Diagnostics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 19.5M AUD | -7.3M AUD | -17.1M AUD |
| 2025 | 19.1M AUD | -11.1M AUD | -8.6M AUD |
| 2024 | 17.0M AUD | -13.1M AUD | -7.6M AUD |
| 2023 | 15.7M AUD | -13.3M AUD | -9.7M AUD |
| 2022 | 16.0M AUD | -63.0M AUD | -29.7M AUD |
Detailed financial statements for Lumos Diagnostics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Lumos Diagnostics
4 dated milestones of Lumos Diagnostics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Lumos Diagnostics is founded.
- Funding First funding round of $15.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
Competitors of Lumos Diagnostics
Lumos Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Access Bio, SD Biosensor, Fluxergy, Module Innovations and DxGen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| accessbio.net | 2001 | Somerset, United States | $22M | 52 | In vitro rapid diagnostic tests, biosensor, and molecular diagnostic products for diagnosis of infectious diseases. | |
| sdbiosensor.com | 2001 | Suwon-si, South Korea | – | – | Biosensors for point-of-care diagnostics are developed by SD Biosensor. | |
| fluxergy.com | 2011 | Irvine, United States | – | 74 | Provides diagnostic devices and software for clinical and veterinary point-of-care testing. | |
| moduleinnovations.com | 2014 | Pune, India | $799,890 | – | Diagnostics strip for bacterial detection | |
| dxgenco.com | 2016 | – | – | – | Point-of-care diagnostic products for diabetes and tuberculosis are provided. | |
| shanxmedtech.com | 2019 | Eindhoven, Netherlands | – | – | In vitro diagnostic platforms for antibiotic testing are provided. | |
| alantissciencesindia.com | 2020 | Manipal, India | – | – | Molecular biology and microbiology research services are provided for diagnostics. | |
| diasurebio.com | 2022 | Seoul, South Korea | $71,475 | – | Rapid antigen tests for infectious diseases are developed. | |
| novo-dx.com | 2022 | Boca Raton, United States | $1.2M | – | Point-of-care diagnostic tests are developed for in-home and clinical use. |
Detailed competitors of Lumos Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lumos Diagnostics
The website of Lumos Diagnostics (lumosdiagnostics.com) receives about 7.3K visits a month.
- Monthly visits7.3K
▼ 2.9% vs previous month
Latest news on Lumos Diagnostics
Complete news archive for Lumos Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Lumos Diagnostics
10 companies that operate in the same segment as Lumos Diagnostics (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lumos Diagnostics
Lumos Diagnostics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Lumos Diagnostics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Sacha Dopheide is the current CEO of Lumos Diagnostics.
Lumos Diagnostics is a funded company, having raised a total of $40M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15M, raised on Feb 2020.
Annual revenue of Lumos Diagnostics is $13.41M as on Jun 30, 2026.
Lumos Diagnostics offer a range of diversified diagnostic products. Lumos platform includes assays, readers, cartridges, and software. Their assays include lateral flow and microfluidics to immunoassay and molecular methodologies. Lumos develops disposable assays suitable for assay test strips and development of custom assay specific analysis algorithms. Th company also has handheld and benchtop readers. The company makes POC cartridge technologies, from lateral flow through to microfluidics. The company has a cloud platform capturing information on device location, test usage, results and associated patient metrics.
Lumos Diagnostics's top competitors include Access Bio, SD Biosensor and Module Innovations.
Yes, Lumos Diagnostics is publicly traded on ASX under the ticker symbol LDX.
Lumos Diagnostics has 3 investors. Key investors include Planet Innovation, Perennial Partners, and Ellerston Capital.
Lumos Diagnostics operates through Lumos Diagnostics, Inc..